Tolerability & Dosing
A critical part of understanding the value of a new therapy is identifying the safety and efficacy of the product. As drugs have become targeted and used for longer periods of time, understanding the tolerability of a therapy and identifying the optimal dosage have emerged as critical components of drug development. Friends of Cancer Research (Friends) worked with stakeholders to propose a definition of tolerability that includes the patient perspective:
“The tolerability of a medical product is the degree to which symptomatic and non-symptomatic adverse events associated with the product’s administration affect the ability or desire of the patient to adhere to the dose or intensity of therapy. A complete understanding of tolerability should include direct measurement from the patient on how they are feeling and functioning while on treatment.”
Friends continued work in this space focuses on key considerations for dosage finding studies that include an understanding of tolerability. Visit us on LinkedIn and Twitter to stay up to date with #FriendsDosing #DoseOptimization.
Selecting the optimal dosage requires a robust understanding of a therapy’s efficacy, safety, and tolerability. Traditionally, early-phase dosing trials aimed to identify the maximum tolerated dose (MTD), an approach designed for cytotoxic chemotherapies where an increase in dose leads to increased tumor suppression. In contrast, newer targeted therapies and immunotherapies may not require dosing at the MTD and a lower dose may provide similar efficacy with an improved safety and tolerability profile for patients.
Recent initiatives like Project Optimus and guidance from the Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) indicate a desire for improved dose optimization in early phase development of oncology drugs and signal a need for renewed approaches to early phase dosing strategies. As standard of care in oncology advances beyond the use of systemic chemotherapies toward the use of more targeted therapies, new strategies and tools are needed to support the timely identification of the optimal dose, including approaches for evaluating and comparing tolerability across dosages.
Data collected throughout drug development provides important insights that enable drug developers, providers, and patients to identify the appropriate drug at dosages that are well tolerated. Earlier characterization of tolerability, including capturing patient-reported outcomes (PROs) during early phase clinical trials, can support a foundational understanding of a therapy’s symptom and functional impacts, inform the design of the registrational trial, and ultimately help to ensure timely identification of the optimal dosage(s) for approval and use in clinical practice.
Since 2013, Friends has convened stakeholders across government, academia, advocacy, and industry to discuss strategies for optimizing the dosing of oncology drugs, including incorporating the patient voice in assessment of tolerability. Scroll through to see how we’ve been working to develop solutions around tolerability for more than ten years.
2013: Friends’ 2013 Annual Conference on Clinical Cancer Research featured a panel discussion and white paper on “Optimizing Dosing of Oncology Drugs.” The white paper identified the challenges of optimizing the dosing of oncology drugs and described potential solutions to improve dosing and administration guidance for health care professionals.
2015: Friends’ 2015 Annual Conference on Clinical Cancer Research featured a panel discussion and white paper on, “Capturing Symptomatic Adverse Events from the Patients’ Perspective: The Potential Role of the National Cancer Institute’s PRO-CTCAE Measurement System.” Since then, many of the operational issues discussed in the paper have been addressed supporting wider implementation and use of the NCI Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
2018: Friends gathered key stakeholders to develop a new working definition of treatment tolerability that incorporates the patient experience by collecting rigorously developed PRO data to inform symptomatic toxicity and functional information. The group aligned on the position that a complete understanding of tolerability should include direct patient measurement of how they are feeling and functioning while on treatment.
2021: Friends’ annual meeting featured a panel and white paper that described current challenges to the implementation of dose-finding studies in oncology, opportunities to improve dosing strategies given these ongoing challenges, and key considerations for selecting appropriate dose optimization strategies in oncology such as expectations for dose-finding studies in the oncology pre-market setting.
2022: Incorporating Patient Reported Outcomes to Inform Dose Selection and Optimization was a topic during Friends’ annual meeting. The white paper identified opportunities, challenges, and solutions for using PROs to inform dose optimization in cancer clinical trials. It also highlighted ways PROs can characterize tolerability and support dosage optimization, a clinical trial design framework for incorporating PROs into dosage optimization studies, and opportunities for using PRO findings from early phase studies to inform later phase study designs and to complement traditional safety data for regulatory decision-making.
2023: We are convening a multi-stakeholder working group to better understand the current landscape of early phase dosing trials and layout strategies to enhance early phase studies through optimal trial designs and the role of patient experience data and digital tools to support a comprehensive understanding of dosage and tolerability.